Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. - Wikidata - wikimedia - TriplyDB

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

http://www.wikidata.org/entity/Q38799449

about

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Advances in Cancer Immunotherapy in Solid Tumors The current status of immunotherapy in peritoneal carcinomatosis.Delivering safer immunotherapies for cancer.Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.Bispecific antibodies: design, therapy, perspectives.Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells.Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project

P2860

Q28072319-27836858-5352-448C-BE4B-5E3508C98E9A Q28080113-31C004A3-4029-459F-96BA-3BC79AE97985 Q38830852-2A049AF3-A259-41A6-9811-30E1A43BC546 Q39330984-3842A470-EE03-41D2-A3E7-D4A013EDA070 Q40644061-45CC89FA-812F-40EA-9551-57F703BF8B37 Q47335259-378DFC68-1AFD-41E3-85A3-2C0CF8529250 Q47696309-6BCCEBF9-0965-445F-9253-9A01E508A243 Q47774455-145F22DF-A96E-4C97-8D21-6DC30B7656D0 Q47786126-CEAF1A56-6739-4865-A22E-5830F44BE509 Q48199074-56E30B35-FF40-4B60-85D8-532FBC75ABD0 Q49195146-920F84E0-0B96-46E4-97AC-D73C316772E7 Q50315378-3EFE6A5E-42A4-474F-947D-D3380BB8D3FF Q55035666-1689A457-655F-4695-A18E-0B9C3CFA04E6 Q58773669-E0FA292F-3F4F-488A-8168-7454E9975B9B

P2860

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

http://www.wikidata.org/entity/Q38799449

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Blinatumomab: a CD19/CD3 bispe ...... th unique anti-tumor efficacy.

@en

type

label

Blinatumomab: a CD19/CD3 bispe ...... th unique anti-tumor efficacy.

@en

prefLabel

Blinatumomab: a CD19/CD3 bispe ...... th unique anti-tumor efficacy.

@en

P1433

Q38799449-B0845673-AE46-4C14-B52F-15CB11BEB915

P1476

Q38799449-FB0D0D3A-5B64-4B58-9389-57C02E434B5A

P2093

Q38799449-1260D737-89EE-46A3-9309-FCABB0EEBC0B

Q38799449-B44B4C9F-BE82-4AB3-B25A-780190F2ADAB

P2860

Q38799449-069FA4CB-670F-49A0-95FE-5DB03C9D61F4

Q38799449-0ADA6F9F-B26A-4D0D-87FD-4F9B98B569AA

Q38799449-21379804-6364-4123-8966-73DF11C6322A

Q38799449-2C51ADB9-229C-440B-9B9F-13F7FB068F59

Q38799449-309421DA-EAE0-40B7-B2A8-4B45D64A656E

Q38799449-33C01F67-C575-42B5-8AB0-192FC1B75892

Q38799449-444C1383-5F6D-4BCD-BB40-792D0222A701

Q38799449-486646DF-0797-4213-8ACE-3B9F5A680C55

Q38799449-4A89AFEE-EA87-4124-B998-6E71FE83DC44

Q38799449-4CE985C5-6A5E-4D2B-8AEF-A1C8839D7135

P304

Q38799449-D61E05A7-E4A0-4C52-AD12-96E28DA0A854

P31

Q38799449-4F9180B8-5A1E-46BE-8764-FF9868E021E3

P356

Q38799449-8A14FE6F-F454-4F6A-9FB3-88490B24526D

P433

Q38799449-BB0BE5F5-B402-487C-A46A-01F446DFDB3D

P478

Q38799449-2FB0885E-FAB3-4E4F-B57D-1BB4A470E40D

P577

Q38799449-252653BE-F0B5-4D52-99D6-AC30B5DD32EC

P698

Q38799449-FBB36483-33F7-4812-B82C-260BD41A55F0

P356

10428194.2016.1161185

P1433

Leukemia & Lymphoma

P1476

Blinatumomab: a CD19/CD3 bispe ...... th unique anti-tumor efficacy.

@en

P2093

Maria-Elisabeth Goebeler

http://www.w3.org/2001/XMLSchema#string

Ralf Bargou

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Novel immunotherapies for hematologic malignancies

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Bispecific T-cell engaging antibodies for cancer therapy

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

Chimeric antigen receptor T cells for sustained remissions in leukemia

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.

P304

1021-1032

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2016.1161185

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27050240

http://www.w3.org/2001/XMLSchema#string